Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.69 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.65 |
| ▸ | MAOA | P21397 | 4/20 | 0.57 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.50 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.50 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4455661 | 1.00 | AURKA (0.69) | AURKAABCG2MAOATXNRD1TXNRD3 | |
| SCHEMBL4453943 | 0.90 | AURKA (0.65) | AURKAABCG2MAOAMAPTMAOB | |
| SCHEMBL4453938 | 0.90 | AURKA (0.65) | AURKAABCG2MAOAMAPTMAOB | |
| SCHEMBL4447938 | 0.89 | AURKA (0.84) | AURKAABCG2MAOATXNRD1TXNRD3 | |
| SCHEMBL4447934 | 0.89 | AURKA (0.84) | AURKAABCG2MAOATXNRD1TXNRD3 | |
| SCHEMBL4456467 | 0.86 | ABCG2 (0.84) | AURKAABCG2MAOATXNRD1TXNRD3 | |
| SCHEMBL4456464 | 0.86 | ABCG2 (0.84) | AURKAABCG2MAOATXNRD1TXNRD3 | |
| SCHEMBL4446391 | 0.83 | ABCG2 (0.73) | AURKAABCG2MAOATP53CYP3A4 | |
| SCHEMBL4446386 | 0.83 | ABCG2 (0.73) | AURKAABCG2MAOATP53CYP3A4 | |
| SCHEMBL4454032 | 0.80 | ABCG2 (0.64) | AURKAABCG2MAOATXNRD1TXNRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182058-A1 | Novel Chalcone Derivatives With Antimitotic Activity | UNIVERSITE JOSEPH FOURIER GRENOBLE I (FR) | 2009-07-16 | — | — | US | claimed |
| US-20090182058-A1 | Novel Chalcone Derivatives With Antimitotic Activity | UNIVERSITE JOSEPH FOURIER GRENOBLE I (FR) | 2009-07-16 | — | — | US | disclosed |
| US-20090182058-A1 | Novel Chalcone Derivatives With Antimitotic Activity | UNIVERSITE JOSEPH FOURIER GRENOBLE I (FR) | 2009-07-16 | — | — | US | disclosed |
| US-20090182058-A1 | Novel Chalcone Derivatives With Antimitotic Activity | UNIVERSITE JOSEPH FOURIER GRENOBLE I (FR) | 2009-07-16 | — | — | US | disclosed |
| WO-2007083060-A2 | NOVEL CHALCONE DERIVATIVES WITH ANTIMITOTIC ACTIVITY | UNIVERSITE CLAUDE BERNARD LYON I (FR) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182058-A1 | Novel Chalcone Derivatives With Antimitotic Activity | ABCE1, CCNE1, FOXM1 | AURKA 747/4885ABCG2 38/4885MAOA 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.